Connect your AI

BioLife Solutions BLFS Debt Securities, Available-for-Sale, Unrealized Loss, Noncurrent

Other financials

Income statement

Revenue$27.5M+24.7%

Gross profit$17.5M+18.2%

Operating income$27.0K+105%

Net income$1.2M+365%

EPS (diluted)$0.02—

Balance sheet

Cash & equivalents$22.8M-65.9%

Total debt$17.4M-35.6%

Total equity$372.2M+5.6%

Total assets$400.9M+1.5%

Cash flow

Operating cash flow-$491.0K-128%

CapEx$167.0K-4.6%

Free cash flow-$658.0K-142%

Valuation

Market cap$1.34B+33.1%

Enterprise value$1.34B+38.1%

P/S13.5×+0.6×

Profitability

Gross margin66.9%—

Operating margin-16.7%—

Net margin-68.7%—

FCF margin-15.9%+18.7pp

Returns & leverage

Return on equity-14.5%-4.7pp

Debt / equity0×0.0×

Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept blfs:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's debt securities, available-for-sale, unrealized loss, noncurrent.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BioLife Solutions's debt securities, available-for-sale, unrealized loss, noncurrent?: BioLife Solutions (BLFS) reported debt securities, available-for-sale, unrealized loss, noncurrent of $100K in Q1 2026.
How has BioLife Solutions's debt securities, available-for-sale, unrealized loss, noncurrent changed year-over-year?: BioLife Solutions's debt securities, available-for-sale, unrealized loss, noncurrent increased by 1328.6% year-over-year, from $7K to $100K.